Takeda submit Japanese NDA for panitumumab in progressed and/or relapse colorectal cancer « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Takeda submit Japanese NDA for panitumumab in progressed and/or relapse colorectal cancer

Posted on June 30, 2008 by crimsoncanary

Takeda have submitted a New Drug Application to the Ministry of Health Labour and Welfare in Japan for panitumumab in the treatment of patients with progressed and/or relapse colorectal cancer. Takeda has Japanese rights for the drug that was developed by Amgen.

Filed under: Kinase receptor | Tagged: ABX-EG, Amgen, EGFR, Monoclonal, panitumumab, regulatory, Takeda, Vectibix

« SGX submit IND for Bcr-Abl inhibitor SGX393 p38 inhibition inhibits hepatitis B virus replication in hepatoma cells »